Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
Precision Perspectives: Navigating Advancements in HR+ / HER2 Negative Breast Cancer Care : Episode 13
Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer
Heather Moore, BCOP, CPP, PharmD, discusses switching from CDK4/6 inhibitors to later lines of therapy, typically due to toxicities, to alleviate symptoms. She emphasizes the goal of finding a new therapy rather than abandoning treatment altogether, and notes that targeted therapy may be necessary in cases of disease progression.
EP: 1.Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer
EP: 2.Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer
EP: 3.CDK4/6 Inhibitors as First-Line Options in Metastatic Breast Cancer
EP: 4.Treatment Algorithms for Early and Metastatic Breast Cancer
EP: 5.NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer
EP: 6.Evaluating the Impact of Metastatic Breast Cancer on Patients
EP: 7.Highlighting the Available CDK4/6 Inhibitors
EP: 8.Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC
EP: 9.Applying NCCN Guidelines in the Treatment of mBC
EP: 10.CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC
EP: 11.Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events
EP: 12.Navigating Financial Barriers: Cost-Saving Strategies and Patient Assistance Programs
Now Viewing
EP: 13.Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer
EP: 14.Academic and Community Practice Collaboration in mBC Treatment
EP: 15.Defining the Standard of Care for Early Breast Cancer Treatment
EP: 16.Balancing Clinical and Economic Factors in Early Breast Cancer Treatment
EP: 17.Alternative Treatments for eBC and mBC
EP: 18.Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective
EP: 19.Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care
EP: 20.Key Takeaways on mBC and eBC
Recent Videos
Related Content
